LENOGRASTIM (cas 135968-09-1) reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization

Add time:08/19/2019    Source:sciencedirect.com

The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving LENOGRASTIM (cas 135968-09-1) vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization.Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes.5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy.The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim.

We also recommend Trading Suppliers and Manufacturers of LENOGRASTIM (cas 135968-09-1). Pls Click Website Link as below: cas 135968-09-1 suppliers

Prev:Synthesis and structure-activity relationships for new 6-fluoroquinoline derivatives with antiplasmodial activity
Next:Original ArticleBiosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and LENOGRASTIM (cas 135968-09-1) (granocyte®): A retrospective multicenter study)